Table 2. Correlation of STC2 protein and mRNA expression with clinicopathological features in HCC (N[%]).

Characteristic	n	STC2 protein positive rate	x2	P	STC2 mRNA positive rate	x2	P
Gender
Male	112	92 (82.1)	0.180	0.669	86 (76.8)	0.022	0.929
Female	88	71 (80.7)			65 (73.9)
Age (years)
<40	45	37 (82.2)	0.194	0.828	35 (77.8)	0.026	0.954
≥40	155	126 (81.3)			116 (74.8)
Tumor diameter (cm)
<5	84	58 (69.05)	0.165	0.009	52 (61.90)	0.108	0.012
≥5	116	105 (90.51)			99 (85.34)
Number of tumors
1	135	111 (82.2)	0.219	0.955	103 (76.3)	0.122	0.295
≥2	65	52 (80.0)			48 (73.8)
Carcinoma emboli in the portal vein
Yes	66	62 (93.94)	0.215	0.036	59 (89.39)	0.181	0.029
No	134	101 (75.37)			92 (68.66)
Combined with cirrhosis
Yes	123	99 (80.5)	0.230	0.369	94 (76.4)	0.122	0.628
No	77	64 (85.3)			57 (74.0)
Degree of tumor differentiation
High and moderate differentiation	35	16 (45.71)	0.251	0.003	13 (37.14)	0.234	0.004
Poor differentiation	165	147 (89.09)			138 (83.64)
Tumor metastasis
Yes	56	52 (92.86)	0.234	0.041	49 (87.50)	0.198	0.031
No	144	112 (77.78)			102 (70.83)
Tumor stage
I–II	51	31 (60.78)	7.543	0.006	29 (56.86)	7.122	0.007
III–IV	149	132 (88.59)			122 (81.88)